Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Since late 2019, the global community has been gripped by the uncertainty surrounding the SARS-CoV-2 pandemic. In November 2021, the emergence of the Omicron variant in South Africa added a new dimension. This study aims to assess the disease's severity and determine the extent to which vaccinations contribute to reducing mortality rates.
Methods: A systematic review and meta-analysis of the epidemiological implications of the omicron variant of SARS-CoV-2 were performed, incorporating an analysis of articles from November 2021that address mortality rates.
Results: The analysis incorporated data from 3,214,869 patients infected with omicron, as presented in 270 articles. A total of 6,782 deaths from the virus were recorded (0.21%). In the analysed articles, the pooled mortality rate was 0.003 and the pooled in-house mortality rate was 0.036. Vaccination is an effective step in preventing death (odds ratio: 0.391, < 0.01).
Conclusion: The mortality rates for the omicron variant are lower than for the preceding delta variant. mRNA vaccination affords secure and effective protection against severe disease and death from omicron.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11153312 | PMC |
| http://dx.doi.org/10.6705/j.jacme.202406_14(2).0001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Association Between Obesity and COVID-19 Severity in Children Differed Between SARS-CoV-2 Variants: A Multicountry Hospital-Based Observational Study.
Pediatr Infect Dis J
September 2025
From the School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland, Australia.
Background: Obesity was a risk factor for severe COVID-19 in children during early outbreaks of ancestral SARS-CoV-2 and the Delta variant. However, the relationship between obesity and COVID-19 severity during the Omicron wave remains unclear.
Methods: This multicenter, observational study included polymerase chain r eaction-confirmed SARS-CoV-2-infected children and adolescents from Australia, Brazil, Italy, Portugal, Switzerland, Thailand, the United Kingdom and the United States hospitalized between January 1, 2020, and March 31, 2022.
Virologic characteristics of SARS-CoV-2 infection across evolving omicron subvariants.
JCI Insight
September 2025
Ragon Institute of Mass General Brigham, Cambridge, United States of America.
Background: The SARS-CoV-2 virus has evolved subvariants since the emergence of the omicron variant in 2021. Whether these changes impact viral shedding and transmissibility is not known.
Methods: POSITIVES is a prospective longitudinal cohort of individuals with mild SARS-CoV-2 infection.
Identification of temperature-insensitive residues in regulating SARS-CoV-2 variants-human ACE2 interaction-a study of molecular dynamics simulation.
Phys Chem Chem Phys
September 2025
School of Chemistry and Chemical Engineering, University of Jinan, Jinan 250022, P. R. China.
The COVID-19 pandemic remains a global health crisis, with successive SARS-CoV-2 variants exhibiting enhanced transmissibility and immune evasion. Notably, the Omicron variant harbors extensive mutations in the spike protein's receptor-binding domain (RBD), altering viral fitness. While temperature is a critical environmental factor modulating viral stability and transmission, its molecular-level effects on variant-specific RBD-human angiotensin-converting enzyme 2 (hACE2) interactions remain underexplored.
View Article and Find Full Text PDFDiscovery and mechanistic insights of dibenzoylmethane as a broad spectrum inhibitor of coronavirus.
PLoS Pathog
September 2025
State Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
Coronavirus, a large family of positive-sense RNA viruses, are responsible for both mild and severe respiratory illnesses, ranging from the common cold to life-threatening conditions. Despite significant advances in vaccine and antiviral development, the high mutability of human coronaviruses (HCoVs), such as SARS-CoV-2, presents a major challenge in treating these infections. Effective, broad-spectrum antiviral drugs are urgently needed to address both current and future HCoV outbreaks.
View Article and Find Full Text PDFBreakthrough SARS-CoV-2 outcomes in immune-disordered people during the Omicron era: a prospective cohort study.
BMJ Public Health
August 2025
Epidemiology and Data Management Unit, Division of Intramural Research, National Institute of Allergy and Infectious Diseases Division of Intramural Research, Bethesda, Maryland, USA.
Introduction: Immune-deficient/disordered people (IDP) elicit a less robust immune response to COVID-19 vaccination than the general US population. Despite millions of IDP at presumed elevated risk, few population-level studies of IDP have been conducted in the Omicron era to evaluate breakthrough infection-related outcomes.
Methods: We followed a prospective cohort of 219 IDP and 63 healthy volunteers (HV) in the USA from April 2021 (Alpha variant peak) to July 2023 (Omicron XBB variant peak).